A Phase 2 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 3rd registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 140th largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2017, is one of 34 in phase 2, and was the 132nd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
Drug: Tirzepatide
Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
Drug: Tirzepatide
Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
Drug: Tirzepatide
Placebo administered by SC injection.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Change From Baseline in Haemoglobin A1c (HbA1c)
Least squares (LS) mean was calculated using mixed model repeated measures model (MMRM) with baseline + baseline BMI group + baseline metformin flag + treatment + time + treatment\*time as fixed factors.
Time frame: Baseline, 3 Months
Percentage of Participants Achieving HbA1c Target of <7.0%
Percentage of participants achieving HbA1c target of \< (less than) 7.0%.
Time frame: 3 Months
Change From Baseline in Fasting Blood Glucose (FBG)
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
Time frame: Baseline, 3 Months
Change From Baseline in Body Weight
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
Time frame: Baseline, 3 Months
Change From Baseline in Waist Circumference
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
Time frame: Baseline, 3 Months
Number of Participants With Anti Drug Antibodies
Number of participants with anti drug antibodies.
Time frame: Baseline through 3 Months
Number of Episodes of Total Hypoglycemia Episodes
Number of episodes of total hypoglycemia episodes with plasma glucose \<= ( less than or equal to) 54 mg/dL.
Time frame: Baseline through 3 Months
Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide
Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide.
Time frame: Week 4, 8 12: Pre-dose
| Milestone | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Started | 26 | 29 | 28 | 28 |
| Received at least one dose of study drug | 26 | 29 | 28 | 28 |
| Completed treatment | 20 | 27 | 22 | 26 |
| Completed | 23 | 28 | 26 | 27 |
| Not completed | 3 | 1 | 2 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 |
Least squares (LS) mean was calculated using mixed model repeated measures model (MMRM) with baseline + baseline BMI group + baseline metformin flag + treatment + time + treatment\*time as fixed factors.
| Percentage of HbA1C | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Haemoglobin A1c (HbA1c) | 0.2 ± 0.21 | -1.7 ± 0.19 | -2.0 ± 0.20 | -1.8 ± 0.19 |
Percentage of participants achieving HbA1c target of \< (less than) 7.0%.
| percentage of participants | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <7.0% | 10 | 74.1 | 87 | 84.6 |
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
| milligrams per deciliter (mg/dL) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) | -12.3 ± 9.27 | -60.7 ± 8.21 | -70.2 ± 8.72 | -74.2 ± 8.67 |
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
| kilogram (kg) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -0.5 ± 0.86 | -5.3 ± 0.78 | -5.5 ± 0.80 | -5.7 ± 0.79 |
LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.
| centimeter (cm) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Waist Circumference | -2.5 ± 1.01 | -4.8 ± 0.90 | -4.9 ± 0.94 | -4.9 ± 0.93 |
Number of participants with anti drug antibodies.
| participants | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Number of Participants With Anti Drug Antibodies | 0 | 10 | 8 | 4 |
Number of episodes of total hypoglycemia episodes with plasma glucose \<= ( less than or equal to) 54 mg/dL.
| Episodes | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| Number of Episodes of Total Hypoglycemia Episodes | 0 | 0 | 0 | 1 |
Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide.
| nanograms per milliliter (ng/mL) | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|
| Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide | 508 ± 366 | 704 ± 518 | 630 ± 414 |
Collected over Baseline through end of study (Up to 15 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/26 (0%) | 0/26 (0%) | 7/26 (26.9%) |
| 4, 8 and 12mg Tirzepatide | 0/29 (0%) | 1/29 (3.4%) | 19/29 (65.5%) |
| 2.5, 5, 10, and 15mg Tirzepatide | 0/28 (0%) | 0/28 (0%) | 18/28 (64.3%) |
| 2.5, 7.5 and 15mg Tirzepatide | 0/28 (0%) | 0/28 (0%) | 22/28 (78.6%) |
| Event | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/26 | 1/29 | 0/28 | 0/28 |
| White blood cell count increasedInvestigations | 0/26 | 1/29 | 0/28 | 0/28 |
| Event | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/26 | 7/29 | 11/28 | 10/28 |
| DiarrhoeaGastrointestinal disorders | 2/26 | 9/29 | 10/28 | 9/28 |
| Decreased appetiteMetabolism and nutrition disorders | 0/26 | 4/29 | 6/28 | 8/28 |
| HeadacheNervous system disorders | 2/26 | 2/29 | 6/28 | 5/28 |
| Abdominal painGastrointestinal disorders | 1/26 | 1/29 | 5/28 | 1/28 |
| ConstipationGastrointestinal disorders | 0/26 | 1/29 | 3/28 | 5/28 |
| VomitingGastrointestinal disorders | 1/26 | 5/29 | 5/28 | 5/28 |
| DyspepsiaGastrointestinal disorders | 0/26 | 5/29 | 3/28 | 3/28 |
| Abdominal distensionGastrointestinal disorders | 0/26 | 0/29 | 3/28 | 2/28 |
| DizzinessNervous system disorders | 2/26 | 0/29 | 1/28 | 3/28 |
| Age, Continuous(years) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 56.0 ± 10.13 | 61.2 ± 7.56 | 55.5 ± 8.54 | 56.6 ± 9.21 | 57.4 ± 9.06 |
| Sex: Female, Male(Participants) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Female | 14 | 14 | 12 | 5 | 45 |
| Male | 12 | 15 | 16 | 23 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 15 | 14 | 14 | 59 |
| Not Hispanic or Latino | 10 | 14 | 14 | 14 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 0 | 3 |
| Asian | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 7 | 5 | 2 | 15 |
| White | 25 | 19 | 20 | 23 | 87 |
| More than one race | 0 | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| United States | 26 | 29 | 28 | 28 | 111 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1C) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 8.23 ± 1.22 | 8.35 ± 0.897 | 8.48 ± 1.171 | 8.35 ± 1.12 | 8.35 ± 1.094 |
| Fasting Blood Glucose (FBG)(millimoles per liter (mmol/L)) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 9.68 ± 3.44 | 9.76 ± 3.03 | 10.40 ± 4.04 | 10.67 ± 4.22 | 10.13 ± 3.69 |
| Body Weight(kilogram (kg)) | Placebo | 4, 8 and 12mg Tirzepatide | 2.5, 5, 10, and 15mg Tirzepatide | 2.5, 7.5 and 15mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 89.58 ± 23.69 | 87.98 ± 17.35 | 88.74 ± 18.21 | 89.59 ± 16.91 | 88.95 ± 18.87 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2017 to primary completion in Apr 2018, 6 months.
Results were first posted in May 2021, 3 years after primary completion. A results delay was requested in Apr 2019.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 6 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide